Your browser doesn't support javascript.
loading
Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis.
Schlienz, Nicolas J; Spindle, Tory R; Cone, Edward J; Herrmann, Evan S; Bigelow, George E; Mitchell, John M; Flegel, Ronald; LoDico, Charles; Vandrey, Ryan.
Affiliation
  • Schlienz NJ; Department of Psychology, University at Buffalo, 313 Diefendorf Hall, Buffalo, NY, 14214, USA.
  • Spindle TR; Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
  • Cone EJ; Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
  • Herrmann ES; Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
  • Bigelow GE; Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
  • Mitchell JM; RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC, 27709, USA.
  • Flegel R; Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Workplace Programs (DWP), 5600 Fishers Lane, Rockville, MD, 20857, USA.
  • LoDico C; Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Workplace Programs (DWP), 5600 Fishers Lane, Rockville, MD, 20857, USA.
  • Vandrey R; Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA. Electronic address: rvandrey@jhmi.edu.
Drug Alcohol Depend ; 211: 107969, 2020 Mar 21.
Article in En | MEDLINE | ID: mdl-32298998
BACKGROUND: Prior controlled cannabis research has mostly focused on smoked cannabis and predominantly included frequent cannabis users. Oral cannabis products ("edibles") make up a large and growing segment of the retail cannabis market. This study sought to characterize the pharmacodynamic effects of oral cannabis among infrequent cannabis users. METHODS: Seventeen healthy adults who had not used cannabis for at least 60 days completed four experimental sessions in which they consumed a cannabis-infused brownie that contained 0, 10, 25, or 50 mg THC. Subjective effects, vital signs, cognitive/psychomotor performance, and blood THC concentrations were assessed before and for 8 h after dosing. RESULTS: Relative to placebo, the 10 mg THC dose produced discriminable subjective drug effects and elevated heart rate but did not alter cognitive/psychomotor performance. The 25 and 50 mg THC doses elicited pronounced subjective effects and markedly impaired cognitive and psychomotor functioning compared with placebo. For all active doses, pharmacodynamic effects did not manifest until 30-60 min after ingestion, and peak effects occurred 1.5-3 h post-administration. Blood THC levels were significantly correlated with some pharmacodynamic drug effects, but were substantially lower than what is typically observed after cannabis inhalation. CONCLUSION: Ingestion of oral cannabis dose-dependently altered subjective drug effects and impaired cognitive performance. Unlike inhaled forms of cannabis for which acute effects occur almost immediately, effects of oral cannabis were considerably delayed. In an era of legalization, education about the time course of drug effects for cannabis edibles is needed to facilitate dose titration and reduce acute overdose incidents.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Drug Alcohol Depend Year: 2020 Document type: Article Affiliation country: Estados Unidos Country of publication: Irlanda

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Drug Alcohol Depend Year: 2020 Document type: Article Affiliation country: Estados Unidos Country of publication: Irlanda